The world of clinical trials is constantly evolving, and China stands at the forefront of this transformation. With a rapidly advancing regulatory environment and growing demand for sophisticated clinical trial support, the need for experienced, in-country partners has never been greater. We sat down with Jane Zhu, Operation Site Leader at Eurofins Central Laboratory Shanghai, to discuss the recent changes, challenges, and opportunities shaping clinical research in China.
This post explores key insights from our conversation, highlighting how Eurofins Central Laboratory is navigating this dynamic landscape. You will learn about significant regulatory shifts, the value of localized services, and the advanced capabilities driving the future of clinical trials in the region.
Evolving with China’s Regulatory Framework
For over two decades, Eurofins Central Laboratory has supported clinical trials in China. During this time, the regulatory landscape has undergone a significant transformation. Jane Zhu points to a major shift toward meeting international standardization requirements, including the full implementation of Good Clinical Practice (GCP) guidelines.
A key milestone was the National Medical Products Administration (NMPA) strengthening its supervision and inspection of clinical trial institutions. This move signaled a commitment to more scientific and comprehensive regulatory measures. As these policies have evolved, the nature of clinical trials has also adjusted, reflecting a more rigorous and standardized approach. This evolution ensures that data generated from trials in China meets global quality standards, facilitating multicenter international studies.
The Strategic Value of Domestic Kit Packing
In 2019, the Shanghai facility added domestic kit packing and distribution to its services, a move that provides immense value for clients conducting trials across China. Sourcing all materials locally is a game-changer, as it completely eliminates the risks and potential delays associated with importation.
This localization offers two major advantages:
1. Improved Turnaround Time (TAT): With local sourcing and assembly, the lab can significantly shorten the time it takes to get kits to clinical sites.
2. Enhanced Flexibility: The team can expedite urgent kit requests for sites anywhere in China, ensuring studies stay on track without logistical hurdles.
Furthermore, this capability allows for customizable kit solutions tailored specifically to the needs of clients in China, providing a level of service that is both efficient and highly responsive.
Expanding to Meet Growing Demand
The rapid increase in clinical trials conducted in China created a clear need for expanded local laboratory capacity. In 2021, Eurofins Central Laboratory responded by relocating to a new, state-of-the-art facility in Shanghai’s Min Hang District. This 10,000-square-foot laboratory was designed to meet the country’s unique regulatory requirements while expanding critical service offerings.
The expansion introduced enhanced capabilities in key areas essential for modern clinical trials. These include:
· Safety & Efficacy testing
· Biomarker analysis under GCLP
· PBMC processing
· Flow cytometry (FACS)
· Molecular testing
This strategic growth ensures that Eurofins has the infrastructure and technology to support the increasing complexity and scale of clinical research in the region.
Advanced Esoteric Testing Capabilities
One of the most significant advantages of the expanded Shanghai lab is its advanced esoteric testing capabilities. With offerings like PBMC processing, flow cytometry, DNA extraction, and qPCR, the facility provides the same high level of service as other top-tier global providers.
These advanced testing platforms are crucial for supporting both global and domestic clinical trials. By offering these services locally, Eurofins Central Laboratory helps clients avoid the logistical complexities of shipping sensitive samples internationally. This provides a competitive edge, enabling sponsors to conduct cutting-edge research efficiently within China.
Ensuring Unwavering Regulatory Compliance
Navigating China’s regulatory environment is paramount, especially for global trials involving Chinese subjects. The Eurofins Central Laboratory Shanghai team has developed robust processes to ensure full compliance. Delegated regional Project Management maintains close communication with clients from the moment a study is awarded.
A critical aspect of this is managing the Human Genetic Resources Administration of China (HGRAC) process. Project Management works directly with sponsors to review all HGRAC documents for accuracy. Starter kits are only delivered to sites after the sponsor has secured full HGRAC approval, preventing any compliance issues.
Beyond study-specific requirements, the laboratory itself operates as a BSL-2 facility and adheres to all local regulations for fire protection, sample handling, storage, and disposal. Standard operating procedures are regularly reviewed and updated to align with the latest regulatory changes, guaranteeing data security and operational integrity.
Looking to the Future of Clinical Trials in China
The journey doesn’t end here. The future for the Eurofins Central Laboratory in Shanghai involves further expansion of specialized capabilities, modeled after our other global central laboratory sites. This will be essential for supporting the next wave of global trials in China.